TABLE 1.
Demographic and clinical description of cohort
| Characteristica | Total (n = 174) |
|---|---|
| Age in yrs, median (range) | 30 (17–61) |
| Male, n (%) | 121 (69.5) |
| HIV infected, n (%) | 98 (56.3) |
| CD4 in HIV-infected patients in cells/μl, median (range) | 174 (6–783) |
| On ART at baseline if HIV infected, n (%) | 28 (28.6) |
| Wt in kg, median (range) | 52 (34–74) |
| Adherence, n (%)b | |
| Missed no doses | 143 (82.2) |
| Missed <2 doses | 10 (5.7) |
| Missed >2 doses | 2 (1.1) |
| Rifampin/isoniazid dose in mg, n (%) | |
| 300/150 | 2 (1.1) |
| 450/225 | 113 (64.9) |
| 600/300 | 59 (33.9) |
| SLCO1B1 mutations | |
| rs11045819 | |
| Wild (CC) | 150 (86.2) |
| Heterozygote (AC) | 24 (13.8) |
| Variant (AA) | 0 (0) |
| rs4149032 | |
| Wild (TT) | 89 (51.1) |
| Heterozygote (CT) | 59 (33.9) |
| Variant (CC) | 26 (14.9) |
| AADAC mutations | |
| rs1803155 | |
| Wild (GG) | 3 (1.7) |
| Heterozygote (CG) | 80 (46.0) |
| Variant (CC) | 91 (52.3) |
| rs61733692 | |
| Wild (TT) | 174 (100) |
| Heterozygote (CT) | 0 (0) |
| Variant (CC) | 0 (0) |
| AADAC haplotype | |
| AADAC*1/*1 | 3 (1.7) |
| AADAC*1/*2 | 80 (46.0) |
| AADAC*2/*2 | 91 (52.3) |
| CES1 mutations | |
| rs12149368 | |
| Wild (GG) | 173 (99.4) |
| Heterozygote (CG) | 1 (0.6) |
| Variant (CC) | 0 (0) |
a
ART, antiretroviral therapy; SLCO1B1, solute carrier organic anion transporter family member 1B1; AADAC, arylacetamide deacetylase; CES1, carboxylesterase 1. n, number of patients.
b
Adherence data were only available for 155 patients.